CLINICAL TRIALS PROFILE FOR CLOZAPINE

All Clinical Trials for CLOZAPINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000372 ↗	Glycine and D-Cycloserine in Schizophrenia	Withdrawn	Massachusetts General Hospital	Phase 3	1998-03-01	The purpose of this study is to compare the effects of D-cycloserine and glycine for treating negative symptoms (such as loss of interest, loss of energy, loss of warmth, and loss of humor) which occur between phases of positive symptoms (marked by hallucinations, delusions, and thought confusions) in schizophrenics. Clozapine is currently the most effective treatment for negative symptoms of schizophrenia. Two other drugs, D-cycloserine and glycine, are being investigated as new treatments. D-cycloserine improves negative symptoms when added to some drugs, but may worsen these symptoms when given with clozapine. Glycine also improves negative symptoms and may still be able to improve these symptoms when given with clozapine. This study gives either D-cycloserine or glycine (or an inactive placebo) with clozapine to determine which is the best combination. Patients will be assigned to 1 of 3 groups. Group 1 will receive D-cycloserine plus clozapine. Group 2 will receive glycine plus clozapine. Group 3 will receive an inactive placebo plus clozapine. Patients will receive these medications for 8 weeks. Negative symptoms of schizophrenia will be monitored through the Scale for the Assessment of Negative Symptoms, Positive symptoms will be monitored through the Positive and Negative Syndrome Scale, and additionally subjects will complete the Brief Psychiatric Rating Scale and the Global Assessment Scale. An individual may be eligible for this study if he/she is 18 to 65 years old and has been diagnosed with schizophrenia.
NCT00001656 ↗	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders	Completed	National Institute of Mental Health (NIMH)	Phase 4	1997-06-01	The purpose of this study is to compare the effectiveness and side effects of the drugs clozapine and olanzapine in children and adolescents with schizophrenia and psychoses. Childhood psychosis is a serious disorder that may have devastating consequences. Effective treatments for the condition are under continual investigation. This study will examine the causes of and offer treatment for childhood psychosis. Participants in this study will undergo psychological tests, blood and urine tests, electroencephalogram (EEG), electrocardiogram (EKG), and magnetic resonance imaging (MRI) scans of the brain for the first 1 to 2 weeks of the study while taking their regular medications. Participants will then be tapered off their medications over 1 to 3 weeks and will continue to stay off medications for an additional 2 days to 3 weeks. During this time, participants will undergo psychiatric, neurological, and cardiac examinations as well as blood tests. After this period without medications, participants will be randomly assigned to receive either clozapine or olanzapine for 8 weeks. An EEG will be performed prior to treatment and after 6 weeks of study medication. Participants who respond well to the study drugs may continue to receive them through their own physician. Participants who do not respond to either clozapine or olanzapine or cannot tolerate their side effects will be treated individually with other drugs until optimum treatment is identified. Regular telephone updates and in person visits to NIH for repeat testing and MRIs will be conducted.
NCT00004826 ↗	Study of Clozapine for the Treatment of Psychosis in Patients With Idiopathic Parkinson's Disease	Completed	Memorial Hospital of Rhode Island	N/A	1993-10-01	OBJECTIVES: I. Determine the efficacy and tolerability of clozapine in ameliorating psychosis in patients with idiopathic Parkinson's disease (PD). II. Determine the adverse effects of clozapine on motor function in this patient population. III. Determine the safety of clozapine in psychotic PD patients taking multiple anti-PD medications. IV. Describe the phenomenology of drug induced psychosis in PD.
NCT00014001 ↗	CATIE- Schizophrenia Trial	Completed	National Institute of Mental Health (NIMH)	Phase 4	2000-12-01	The CATIE Schizophrenia Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The schizophrenia trial is being conducted to determine the long-term effects and usefulness of antipsychotic medications in persons with schizophrenia. It is designed for people with schizophrenia who may benefit from a medication change. The study involves the newer atypical antipsychotics (olanzapine, quetiapine, risperidone, clozapine, and ziprasidone)and the typical antipsychotics (perphenazine and fluphenazine decanoate). All participants will receive an initial comprehensive medical and psychiatric evaluation and will be closely followed throughout the study. For most participants the study will last up to 18 months. Everyone in the study will be offered an educational program about schizophrenia and family members will be encouraged to participate.
NCT00029458 ↗	Clozapine for Treatment-Resistant Mania	Completed	National Institute of Mental Health (NIMH)	Phase 2	2002-01-01	The purpose of this study is to evaluate the safety and effectiveness of clozapine as a treatment for the manic phase of bipolar disorder. A significant proportion of manic patients either do not respond adequately to conventional treatment or cannot tolerate the adverse effects associated with therapeutic doses of these agents. Clozapine may be a safe and effective treatment for mania. However, the efficacy of clozapine as an alternative therapy in treatment-resistant bipolar disorder mania has not been extensively researched. The study will be conducted in three phases. Phase 1 is a screening phase that will take place for 2 to 7 days. Participants will undergo a baseline positron emission tomography (PET) scan of the brain at the end of this period. In Phase 2, participants will be randomly assigned to receive either clozapine or placebo (an inactive pill) for 3 weeks. They may also receive lorazepam for the first 10 days of Phase 2. After 3 weeks, patients treated with clozapine will undergo a second PET scan. During Phase 3, participants who received placebo and did not improve will be offered clozapine for 3 weeks. Those who received clozapine and did not improve will receive other treatment for 3 weeks. At the end of Phase 3, participants who were treated with clozapine will have another PET scan.
NCT00031317 ↗	Evaluation of Clonazepam and Paroxetine for Panic Disorder With Depression	Completed	National Institute of Mental Health (NIMH)	Phase 4	2002-02-01	The purpose of this study is to examine the safety and effectiveness of the drug combination paroxetine and clonazepam in treating people with panic disorder (PD) and major depression. The main goal in treating people with PD is to rapidly reduce symptom severity and improve functioning. While numerous drug therapies have been used to treat PD, these treatments are limited by variable response rates and suboptimal side effect profiles. Evidence suggests that clonazepam given with a selective serotonin reuptake inhibitor (SSRI) can facilitate a rapid reduction in PD symptoms. However, it is unclear whether comorbid depression influences treatment response to the clonazepam and SSRI regimen. This study will examine whether combined treatment with clonazepam and the SSRI paroxetine will accelerate clinical response in participants with PD and comorbid depression. This study will also examine whether the benefits of treatment will be sustained until the end of the study despite tapering of clonazepam at the midpoint of the study. Participants in this study will be screened with medical and psychiatric interviews, a physical examination, electrocardiogram (ECG), and blood tests. Participants will then be randomly assigned to receive either paroxetine plus clonazepam or paroxetine plus placebo (an inactive pill) for 12 weeks. Participants will have weekly clinic visits during which symptoms and drug side effects will be checked and an interview to evaluate panic disorder and depression symptoms will be conducted.

Clinical Trial Conditions for CLOZAPINE

Condition Name

Condition Name for CLOZAPINE
Intervention	Trials
Schizophrenia	129
Schizoaffective Disorder	30
Bipolar Disorder	11
Psychotic Disorders	7

Condition MeSH

Condition MeSH for CLOZAPINE
Intervention	Trials
Schizophrenia	148
Psychotic Disorders	52
Disease	25
Mental Disorders	20

Clinical Trial Locations for CLOZAPINE

Trials by Country

Trials by Country for CLOZAPINE
Location	Trials
United States	204
India	22
Canada	14
Spain	14
United Kingdom	14

Trials by US State

Trials by US State for CLOZAPINE
Location	Trials
Massachusetts	22
New York	21
Maryland	17
California	15
Missouri	12

Clinical Trial Progress for CLOZAPINE

Clinical Trial Phase

Clinical Trial Phase for CLOZAPINE
Clinical Trial Phase	Trials
PHASE4	5
PHASE3	1
PHASE2	2

Clinical Trial Status

Clinical Trial Status for CLOZAPINE
Clinical Trial Phase	Trials
Completed	119
Unknown status	18
Recruiting	17

Clinical Trial Sponsors for CLOZAPINE

Sponsor Name

Sponsor Name for CLOZAPINE
Sponsor	Trials
National Institute of Mental Health (NIMH)	23
Dartmouth-Hitchcock Medical Center	10
University of Maryland	9

Sponsor Type

Sponsor Type for CLOZAPINE
Sponsor	Trials
Other	342
Industry	55
NIH	31

Clozapine Clinical Trials Update, Market Analysis, and Patent/Exclusivity Outlook

Last updated: July 28, 2026

What is the current clinical development and trial pipeline status for clozapine?

Clozapine is an established antipsychotic with long-running clinical use for treatment-resistant schizophrenia (TRS) and other off-label/adjunct applications. Its “clinical trials update” in 2026 is dominated by incremental studies (comparative effectiveness, dosing optimization, safety monitoring, real-world cohorts, and long-term outcomes) rather than broad first-in-class development.

Practical pipeline reality for clozapine

• Late-stage filings: Most new activity is post-approval evidence generation (registry studies, observational cohorts, pragmatic randomized trials) rather than NDA/BLA-grade submissions.
• Technology focus: Programs frequently target risk mitigation (agranulocytosis monitoring protocols), adherence, pharmacovigilance, and patient stratification using biomarkers or clinical prediction models.
• Formulation/device work: Where development exists, it tends to target delivery and tolerability rather than mechanism re-invention.

How big is the clozapine market today, and which therapeutic segments drive revenue?

Clozapine market revenues come primarily from:

• Treatment-resistant schizophrenia (core label in most major jurisdictions).
• Reduction of suicidality risk in schizophrenia/psychotic disorders where specific label language exists (varies by country/regulator).
• Maintenance in chronic schizophrenia populations who fail other antipsychotics.

Key demand drivers

• TRS prevalence in schizophrenia populations.
• Physician reliance on clozapine after multiple antipsychotic failures.
• Ongoing preference in certain geographies for clozapine over newer agents for TRS due to evidence depth and clinical familiarity.
• Health-system protocols for blood monitoring and prescriber certification that shape adoption rates.

Supply-side constraints that affect market dynamics

• REMS-style hematologic monitoring infrastructure (US) and parallel risk management programs internationally.
• Generic availability in many markets reduces brand pricing power but does not eliminate demand because clozapine is still “must-use” in TRS.

What are market projections for clozapine through 2030, and what would change the outlook?

Base-case market trajectory

• Pricing pressure from generics typically limits value growth.
• Volume growth depends on diagnosis rates, TRS recognition, and access to hematology monitoring infrastructure.
• Real-world evidence and guideline updates support continued steady utilization.

Upside scenarios

• Faster adoption via simplified monitoring approaches or improved adherence pathways.
• Geographic expansion where TRS pathways and monitoring capacity are scaling.
• Evidence strengthening for specific subpopulations (early TRS identification, comorbidity-defined responses).

Downside scenarios

• Therapeutic substitution by newer antipsychotics with better tolerability profiles for borderline TRS cases.
• Monitoring-related access constraints (cost, staffing, lab turnaround time) that slow initiation.
• Safety events that trigger tighter restrictions or burdensome prescriber workflows.

Which companies commercialize clozapine, and how does competitive structure affect pricing?

Clozapine is widely marketed, typically as:

• Generic tablets in many jurisdictions.
• Multiple generics competing by dosage strengths and supply reliability.
• Less differentiation by mechanism, more by distribution, packaging, and stability of supply for the required strengths.

Competitive implications

• The market behaves like a “high-utilization, high-monitoring, low-molecule differentiation” product.
• Consolidation risk: distributors and manufacturing network reliability become material to shortages and reimbursement behavior.

What patents protect clozapine, and when do clozapine patents expire or lose exclusivity?

Clozapine is a decades-old active ingredient. For market access, exclusivity discussion in clozapine is generally less about active-ingredient composition of matter and more about:

• Specific formulation patents (fixed-dose combinations, specific release profiles, optimized salt/formulation forms).
• Method-of-use patents (narrow clinical indications, monitoring strategies, or dosing regimens).
• Manufacturing process patents (sterility/quality or specific process steps are more common in newer reformulations than in the base drug).

Exclusivity timeline mechanics

• Generic competition has been active for years in major markets.
• Any remaining exclusivity is commonly tied to a specific formulation/indication strategy rather than the parent drug molecule.

What is the Orange Book status of clozapine, and does it materially block generic entry?

Clozapine’s active ingredient status in the FDA system generally does not create an ongoing composition-of-matter barrier because generics exist broadly. The operative question for generic entry risk in 2026 is:

• whether any listed patents still cover a specific dosage form or approved method-of-use, and
• whether those patents are expired, withdrawn, or still enforceable.

Featured-snippet style answer

• Clozapine generally has limited patent exclusivity barriers at the active-ingredient level because it has long been off active patent protection.
• Residual barriers, where present, typically relate to formulation-specific or use-specific patent listings for particular approved products.

What generic entry risks exist for clozapine in 2026?

For clozapine, generic entry risk is usually low at the active ingredient level because:

• numerous ANDA approvals exist across strengths,
• supply chains are established,
• and remaining enforceability tends to be limited to narrow, product-specific claims (if any).

Where risk can still occur:

• a generic may avoid infringement on listed patents by filing a different paragraph certification strategy,
• or may require a label carve-out for method-of-use protections.

What patent litigation affects clozapine?

Patent litigation involving clozapine itself has historically been intermittent and typically tied to product-specific patents (formulations, method-of-use claims, or manufacturing IP) rather than core molecule claims. In the current cycle, most litigation risk should be assessed by:

• whether any enforceable listed patents remain for particular dosages/labeling,
• whether there are settlements that constrain timing for a specific product.

Commercial consequence

• Even when litigation exists, it usually impacts specific product SKUs rather than the overall clozapine market.

How does clozapine compare with alternative antipsychotics for TRS, and what drives substitution risk?

Clozapine is the standard-of-care TRS option in many guidelines due to:

• evidence for symptom control in patients who fail multiple antipsychotics,
• long clinical experience.

Substitution pressure

• Newer antipsychotics and combinations can reduce clozapine initiation in some systems by improving tolerability, though they often do not replicate clozapine’s response rates in established TRS populations.
• Monitoring burden can also create switching in early-stage treatment paths rather than in established TRS.

Where clozapine remains resilient

• Patients with demonstrated multiple antipsychotic failures.
• Systems with established monitoring infrastructure and prescriber certification pathways.

What formulations are protected by patents, and are there still meaningful IP barriers by dosage form?

The most common residual IP categories for legacy drugs like clozapine are:

• formulation/process improvements for specific strengths and manufacturing routes,
• stability and bioavailability optimization,
• sometimes packaging or excipient systems.

Market impact

• Even if narrow formulation patents exist, generic firms can often enter via alternative manufacturing methods and/or by marketing strengths not covered by enforceable claims.

What clinical evidence updates are most likely to change dosing and safety practice for clozapine?

Clinical updates that can shift utilization patterns include:

• improved monitoring compliance models (digital reminders, lab turnaround improvements),
• stratified hematologic risk monitoring schedules (where supported by data),
• real-world safety analyses on infections, myocarditis incidence, metabolic outcomes, and adherence patterns.

These studies tend to influence:

• time-to-initiation,
• persistence on treatment,
• and downstream hospitalization rates in TRS cohorts.

What FDA regulatory status and REMS considerations matter for clozapine in 2026?

Clozapine is regulated with stringent hematologic monitoring requirements (US REMS framework). The dominant regulatory consequence is operational:

• prescriber and lab certification workflow,
• patient enrollment and adherence tracking,
• monitoring cadence management.

Why it matters commercially

• delays in enrollment and monitoring capacity can slow new starts even where clinical need is high,
• supply continuity plus stable monitoring workflows reduces treatment interruption risk.

Key commercial projections and scenario table for clozapine (2030 horizon)

Driver	Base-case assumption	Upside	Downside	Net effect
TRS recognition and referral	steady improvement	faster TRS identification	slower access	supports volume
Generic pricing	sustained erosion	tender-based pricing lift in some geos	continued compression	limits value growth
Monitoring infrastructure	stable in major markets	automation and process optimization	lab bottlenecks	affects initiation speed
Safety perception	stable	improved protocols reduce events	negative safety narratives	affects adherence
Substitution by newer antipsychotics	modest	limited TRS control	greater diversion to alternatives	affects initiation and persistence

Key Takeaways

• Clozapine’s 2026 market outlook is driven more by TRS referral patterns, monitoring access, and generic pricing than by new mechanism-of-action innovation.
• Clinical “updates” in practice skew toward comparative effectiveness, monitoring optimization, and long-term outcome evidence rather than transformative new indications.
• Patent exclusivity barriers at the active-ingredient level are generally not the principal constraint; if any enforceable IP exists, it is typically formulation- or product-specific.
• Operational REMS and blood monitoring capacity are the real-world bottlenecks that can move volume and persistence.

FAQs

1. How does the US clozapine REMS impact time-to-treatment and persistence?
2. Are there clozapine formulation changes (different release profiles or excipients) that affect generic bioequivalence or substitution?
3. Do method-of-use patents for clozapine still restrict labeling and generic launches?
4. What real-world outcomes (hospitalization, mortality, adherence) most correlate with clozapine persistence in TRS populations?
5. How do healthcare system blood monitoring workflows influence clozapine market growth by country?

References

1. FDA. Clozapine REMS and prescribing information resources (US).
2. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Clozapine listings (accessed via FDA databases).
3. EMA. Clozapine product information and risk management guidance for EU marketing authorization holders (country-specific product pages).
4. ClinicalTrials.gov. Clozapine study listings (ongoing and completed interventional/observational studies).